Top ADHD research for psychiatrists

A 2015 meta-analysis of 175 research studies indicated 7.2% of children aged 18 years and younger worldwide had attention-deficit/hyperactivity disorder.

Prevalence of adult ADHD was approximately 3.4% worldwide, according to a screening for DSM-IV ADHD among 11,422 adults in 10 countries in North and South America, Europe and the Middle East.

In the U.S., analysis of parent-reported data from the 2011 to 2013 National Health Interview Survey indicated ADHD in 2.7% of children aged 4 to 5 years, 9.5% of children aged 6 to 11 years and 11.8% of children aged 12 to 17 years.

Healio.com/Psychiatry gathered the most relevant research on ADHD in children and adults for psychiatrists and clinicians treating ADHD.

Combination therapy more effective than monotherapy for ADHD

A combination of d-methylphenidate and guanfacine was more effective for attention-deficit/hyperactivity disorder than either treatment alone, according to recent findings. Read more

Tris Pharma launches online resource for clinicians prescribing ADHD treatment

Tris Pharma Inc. recently announced the launch of a new website for health care professionals prescribing Dyanavel XR, extended-release oral suspension, CII, an extended-release liquid amphetamine, for attention-deficit/hyperactivity disorder in children aged 6 years and older. Read more

AAP provides guidance on treating acute pediatric mental health, behavioral problems

The American Academy of Pediatrics’ Committee on Pediatric Emergency Medicine and the American College of Emergency Physicians’ Pediatric Emergency Medicine Committee recently released a two-part clinical report to address knowledge gaps regarding pediatric mental health emergencies. Read more

Methylphenidate affects dopaminergic system in children, not adults

Recent findings indicated treatment with methylphenidate for attention-deficit/hyperactivity disorder significantly affected the dopaminergic system in children but not adults. Read more

SHP465-306 safe, effective for adult ADHD

SHP465-306, a triple-bead mixed amphetamine salts capsule from Shire, was effective and safe for attention-deficit/hyperactivity disorder, according to recent findings. Read more

References:

Fayyad J, et al. Br J Psychiatry. 2007;190:402-409.

Pastor P, et al. NCHS Data Brief. 2015;(201):201.

Thomas R, et al. Pediatrics. 2015; doi:10.1542/peds.2014-3482.

http://www.help4adhd.org/Understanding-ADHD/About-ADHD/Data-and-Statistics/General-Prevalence.aspx